Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Cara Therapeutics Presents Late-Breaking Results Of KARE Phase 2 Trial Of Oral Difelikefalin In Atopic Dermatitis Patients With Moderate-to-Severe Pruritus At The 2021 European Academy Of Dermatology And Venereology Virtual Congress

Cara Therapeutics, Inc. (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid

CARA